GPT and Hepatitis: Remdesivir is not recommended for patients with baseline ALT ≥5 x ULN, and should be stopped if any of the following conditions occur during dosing: (I) ALT ≥5 x ULN; (II) ALT elevation accompanied by signs or symptoms of liver inflammation; or (III) ALT elevation accompanied by elevated conjugated bilirubin, ALP or international normalized ratio (INR).